According to the Complaint, Sarepta focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. Sarepta’s products pipeline includes, among other drug candidates, golodirsen for the treatment of duchenne muscular dystrophy.

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding Sarepta’s business, operational and compliance policies. Specifically, the Complaint alleges Defendants made false and/or misleading statements and/or failed to disclose that: (i) golodirsen posed significant safety risks to patients; (ii) consequently, the NDA package for golodirsen’s accelerated approval was unlikely to receive FDA approval; and (iii) as a result, Sarepta’s public statements were materially false and misleading at all relevant times.

On Decemember 17, 2019, the Court issued an Order appointing Lead Plaintiff and Counsel.

This case was voluntarily dismissed on February 13, 2020.